Objectives: To assess real-world treatment patterns of targeted therapies after failure of first-line tyrosine kinase inhibitors in patients with advanced renal cell carcinoma. Methods: A large, retrospective review of medical charts of patients with advanced renal cell carcinoma in the USA was carried out. Descriptive statistics were used to summarize physicians' and patients' characteristics, treatment sequences, and reasons for treatment choices. P-values were calculated using v 2 -tests for categorical variables and Wilcoxon rank-sum tests for continuous variables. A descriptive comparison was carried out between current results and those of a previous treatment pattern study conducted in 2012 to identify changes in treatment patterns over time. Results: Sunitinib and everolimus remained the most commonly-used first and second targeted therapies, respectively. Among patients who continued to a third targeted therapy, everolimus and axitinib were the most commonly-used treatments after second targeted therapy with a tyrosine kinase inhibitor and a mammalian target of rapamycin inhibitor, respectively. The use of pazopanib as first targeted therapy, and of axitinib and sorafenib as second targeted therapies, increased over time. Efficacy, treatment guidelines and a different mechanism of action were the main reasons given by physicians for choosing among second targeted therapies after failure of a first tyrosine kinase inhibitor.
Abbreviations & Acronyms aRCC = advanced RCC AXIS = axitinib versus sorafenib in advanced renal cell carcinoma ECOG = Eastern Cooperative Oncology Group eCRF = electronic case report form MOA = mechanism of action mTOR = mammalian target of rapamycin METEOR = metastatic renal cell carcinoma, cabozantinib (XL184) versus everolimus mRCC = metastatic RCC NCCN = National Comprehensive Cancer Network RCC = renal cell carcinoma RCT = randomized clinical trial RECORD = renal cell cancer treatment with oral RAD001 given daily TKI = tyrosine kinase inhibitors TT = targeted therapy VEGFR = vascular endothelial growth factor receptor VEGF = vascular endothelial growth factor Correspondence: James E Signorovitch Ph.D., Analysis Group, Inc., 111 Huntington Ave, 14th floor, Boston, MA 02199, USA. Email: james.signorovitch@analysis group.com Introduction RCC is the most prevalent form of kidney cancer in adults, accounting for up to 95% of kidney cancer diagnoses in the USA. At diagnosis, approximately 30% of patients present with aRCC, 1,2 and 20-50% of patients who undergo nephrectomy ultimately develop aRCC.
Because of their improved efficacy, 5, 7, 8 targeted therapies have nearly completely replaced cytokines to become the current standard of care for patients with aRCC. 7, 9, 10 However, within a year of starting a first targeted therapy, most patients develop resistance to treatment and receive a second and, often, a third targeted therapy. 5, 8, [11] [12] [13] [14] [15] Thus, deciding which targeted therapies should be used after failure of the first one -and in which sequence -amid a growing number of treatment options is a challenge. 10, 16 Current NCCN guidelines recommend the use of VEGFR TKIs as first targeted therapy in patients with good-to-intermediate prognosis and the use of temsirolimus in patients with poor prognosis. 16, 17 After failure of a first TKI, NCCN guidelines recommend using either another TKI, such as axitinib, or switching to a different MOA with everolimus. [16] [17] [18] Phase III trials, such as the AXIS trial comparing axitinib with sorafenib 15 and the RECORD-1 trial comparing everolimus with a placebo, have shown the efficacy of these treatments as second targeted therapies.
14 Real-world assessments of the outcomes of patients treated with different TKIs versus mTOR inhibitors after failure of a first TKI have used different study designs and reported heterogeneous results, leading to no clear indication of which class of agents should be used as second targeted therapy. 9, 18 Given the lack of consensus on the optimal treatment sequences for aRCC, available targeted therapies are likely to be used differently across clinical practices. For this reason, several studies have been carried out to assess real-world treatment patterns. 11, [19] [20] [21] [22] [23] [24] However, current treatment patterns, reflecting the adoption of newer treatments such as pazopanib (approved in October 2009) and axitinib (approved in March 2012), are not adequately captured by these studies based on older data. Because prescription habits are likely to change as physicians become more familiar with newer therapies, it is important to monitor how treatment patterns evolve over time to provide healthcare stakeholders with evidence from current real-world practice that can complement clinical trial data and inform clinical decision-making.
The present study aimed to provide a comprehensive and updated description of real-world treatment patterns in the USA among aRCC patients receiving sequential targeted therapies after a first TKI failure. To identify changes in treatment patterns over time, the use of various first and second targeted therapies in the present study were descriptively compared with those previously reported by the same authors in a similarly designed study conducted in 2012. 11 
Methods

Data source
Medical oncologists and hematologists/oncologists were recruited in the USA from a nationwide panel of physicians from June 2014 to July 2014. Physicians were required to have treated at least three patients with aRCC in the preceding year. Each eligible physician was invited to randomly select and abstract data from up to five patient charts meeting the inclusion criteria listed below (see Study population). A standardized eCRF was developed by the study investigators, pilot-tested by two oncologists and used by the eligible physicians to extract relevant chart information. Patient data were anonymous and non-identifiable. Exemption from full institutional review board review was granted by the New England Institutional Review Board.
Study population
To be included in the study, patients were required to meet the following criteria: (i) to be ≥18 years of age; (ii) to have been diagnosed with mRCC; (iii) to have received their first targeted therapy with a TKI (sunitinib, sorafenib, axitinib or pazopanib) after being diagnosed with mRCC; (iv) to have discontinued the first TKI for medical reasons (e.g. disease progression, non-response without progression, drug intolerance); (v) to have initiated a second targeted therapy with either a TKI or an mTOR inhibitor (sorafenib, axitinib, sunitinib, pazopanib, everolimus or temsirolimus) between 1 February 2012 and 31 January 2013; and (vi) to have medical records available for review from initiation of the first targeted therapy to either the most recent follow up or death.
Study measures
Physicians were characterized by their medical specialty, practice setting and the number of years spent practicing. Recorded patient characteristics included age at initial aRCC diagnosis, sex, aRCC disease history (aRCC duration, presence of metastasized disease at initial RCC diagnosis), characteristics at first targeted therapy (nephrectomy, concurrent treatments [yes/no], physician-assessed clinical benefit and clinical progression), characteristics at second targeted therapy (duration of first TKI, sites of metastases, clear cell histologic subtype [yes/no], concurrent treatments [yes/no], ECOG performance status and comorbidities).
To characterize treatment sequences, the numbers and proportions of patients receiving different types of targeted therapies as first, second and third therapies were summarized at the individual drug level.
For each type of second targeted therapy, physicians' single most important reason for choosing that treatment was reported. Choices included treatment guidelines, efficacy of drug as show in RCTs, different MOA than prior therapy, response to first targeted therapy, as a participant in a clinical trial, patient preference, experience of peers (other physicians) with the drug, physicians' own experience with the drug, comorbid conditions, cost of drug/patient copay/access, tolerability of drug, route of administration (e.g. IV vs oral) and potential need for dose escalation.
Statistical analysis
Descriptive statistics were used to summarize physicians' and patients' characteristics, treatment sequences, and reasons for treatment choices. Means and standard deviations were reported for continuous variables. Frequencies and percentages were reported for categorical variables. Patients' characteristics and reasons for treatment choices were compared among those treated with different second targeted therapies. P-values were calculated using v 2 -tests for categorical variables and Wilcoxon rank-sum tests for continuous variables. To characterize changes in treatment patterns from 2012 to 2014, the proportions of patients treated with different first and second targeted therapies were compared with those reported by a 2012 treatment pattern study.
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Results
A total of 318 physicians participated and contributed medical charts from 1173 patients with aRCC. Approximately 62% of participating physicians were medical oncologists, whereas 75% practiced in the community setting. Median time in practice was 13.5 years. Physicians' characteristics are further summarized in Table 1 . Among the sampled patients, the mean age was 61 years and 33% were female. In 63% of the sample, the duration of aRCC at second targeted therapy initiation was 12 months or more. Mean follow-up time from initiation of second targeted therapy was 14.6 months. A total of 71% of patients experienced physician-reported clinical benefit on first targeted therapy; 79% eventually experienced physician-reported clinical progression. The most common metastatic sites at second targeted therapy initiation were the lung (55%), lymph nodes (40%), bone (35%), liver (29%) and adrenal glands (17%). Additionally, 77% of patients had clear cell RCC, and 82% had an ECOG score of 0 or 1 at initiation of second targeted therapy. Common comorbidities included diabetes mellitus (29%), hypercholesterolemia (38%) and hypertension (41%). Patients' characteristics are further summarized in Table 2 .
Sunitinib was the most common first targeted therapy (74%), followed by pazopanib (13%) and sorafenib (11%) (Fig. 1) . Everolimus was the most common second targeted therapy (28%), followed by sorafenib (22%), temsirolimus (18%), pazopanib (14%), axitinib (11%) and sunitinib (8%). Nearly half of all patients (47%) were still on their second targeted therapy at the last contact. Of those patients who received a TKI as their second targeted therapy and were observed to continue to a third targeted therapy (n = 60), the majority (67%) received an mTOR inhibitor as their third targeted therapy, with everolimus being the most common treatment. Of those patients who received an mTOR inhibitor as their second targeted therapy and were observed to continue to a third targeted therapy (n = 63), the majority (95%) received a TKI as their third targeted therapy, with axitinib being the most common treatment.
The reasons indicated by physicians as the single most important for the choice of second targeted therapy included efficacy of drug in RCTs (32% of physicians), treatment guidelines (29%) and a different MOA than prior therapy (11%). Reasons for treatment choices are further summarized in Table 3 .
From 2012 to 2014, among first targeted therapies, sunitinib remained the most common therapy, while the use of pazopanib increased over time; among second targeted therapies, everolimus remained the most common therapy, while the use of axitinib and sorafenib increased over time. Changes in treatment patterns from 2012 to 2014 are further summarized in Table 4 .
Discussion
The approval of several targeted therapies for aRCC in the span of just a few years has prompted efforts to determine the optimal sequence of treatments for patients who fail the first targeted therapy. To facilitate the identification of such a sequence and, ultimately, guide treatment decisions, it is important to complement clinical trial data with an understanding of how targeted therapies are used in daily clinical practice. The present study used medical chart data to provide an updated overview of real-world treatment patterns in patients with aRCC who fail a first TKI in the USA, including patients receiving more recently approved targeted therapies such as axitinib and pazopanib. This study builds on and adds to earlier descriptions of treatment patterns, which included much smaller numbers of patients receiving recently approved treatments. 11, [19] [20] [21] [22] [23] [24] The results of the present study showed that, at initiation of the second targeted therapy, patients' characteristics differed across treatments. In particular, lung metastases were observed more frequently in patients treated with everolimus and axitinib than in patients treated with sorafenib or sunitinib. It should be noted that second targeted therapies were each compared with everolimus; pairwise comparisons between individual second targeted therapies would be difficult to interpret clinically. Consistent with our previous treatment pattern study conducted in 2012, sunitinib remained the most frequently used first targeted therapy, whereas everolimus remained the most frequently used second targeted therapy. 11 Furthermore, the use of pazopanib as first targeted therapy and of axitinib and sorafenib as second targeted therapies increased over time. A recent phase III trial (AXIS) has shown that, although axitinib is associated with longer progression-free survival than sorafenib, the overall survival results are comparable. 25 Among patients who were observed to continue to a third targeted therapy, everolimus was the most commonly used treatment after a second targeted therapy with a TKI, whereas axitinib was the most commonly used treatment after a second targeted therapy with an mTOR inhibitor, suggesting that physicians tended to switch MOA (from TKI to mTOR inhibitors and vice versa) after failure of second targeted therapy. However, some studies suggest that switching from VEGFR- P-values were estimated from v 2 -tests for categorical variables and Wilcoxon rank-sum tests for continuous variables for comparison of other second targeted therapies with everolimus. *P < 0.05, **P < 0.01. †Patients with missing values were excluded from the analysis for that particular variable. ‡Follow-up time of second targeted therapy was defined as the time-period between the initial prescription date of second targeted therapy and the earlier of the last followup date or death. §Duration of mRCC was defined as the time-period between diagnosis of mRCC and last follow-up date or death; one patient had the last follow-up or death date missing and was excluded from the analyses. ¶Patients who had metastasized RCC at initial RCC diagnosis were patients whose mRCC diagnosis date and initial RCC diagnosis date were the same. † †Duration of mRCC at second targeted therapy initiation was defined as the time-period between the initial diagnosis of mRCC and the initial prescription date of the second targeted therapy.
TKI to mTOR does not necessarily imply changing MOA, as mTOR could be just another way of inhibiting angiogenesis, which, in RCC, is heavily driven by VEGF. 26, 27 Physician-reported reasons for treatment choices help shed light on the criteria used to make decisions regarding second targeted therapy after failure of a first TKI. In all cases, the efficacy reported in RCTs and treatment guidelines were found to be the two most commonly selected "single most important" reasons for a physician's choice. Phase III RCTs, such as the RECORD-1 14 and AXIS trials, 15 have established the efficacy of everolimus and axitinib as second targeted therapies. Based largely on such clinical trial evidence, NCCN guidelines recommend the use of everolimus and axitinib after failure with first TKI with category 1 recommendation. 17 Although head-to-head randomized comparisons are not available for all pairs of second targeted therapies, indirect comparisons of trial data have shown similar effectiveness for everolimus and axitinib. 28 In addition, in the case of the mTOR inhibitors everolimus and temsirolimus, a MOA different from that of a previous TKI also played a considerable role in treatment decisions. Finally, other factors, such as physicians' prior experience with a treatment, safety and dosing convenience, were often considered by physicians in their decision-making process.
As more clinical data become available, and new therapies are approved by the Food and Drug Administration, there will be a continuing need to better understand how different therapies are being integrated into the care of aRCC. The recently published findings of the phase III METEOR trial for cabozantinib, 29 a novel TKI of VEGFR and c-met, and the Checkmate-025 trial for nivolumab, 30 an anti-PD1 immunotherapy, are likely to influence treatment decisions in the near future, especially in the second targeted therapy setting. Amid such a rapidly evolving treatment landscape, further studies are required to evaluate real-world patterns of care and provide healthcare stakeholders with important and timely information on how to optimize treatment strategies.
The present study had several limitations. First, reviews of medical charts are subject to a non-random selection of patients, as well as the presence of missing or incorrect data. Second, the treatment patterns found in the USA patient population considered here might not be generalizable to other regions. Third, the comparison between the present study and a previous 2012 treatment pattern study was descriptive in nature and did not adjust for differences in patient characteristics. 11 Finally, as most physicians in the present sample practiced in the community setting, it would be interesting to see whether having a higher proportion of physicians practicing in other settings (e.g. academic) would change, and to which extent, the treatment pattern results presented here.
In conclusion, in the present large retrospective review of medical charts of patients with aRCC in the USA, sunitinib and everolimus were the most commonly used first and second targeted therapy, respectively. Among patients who continued to a third targeted therapy, everolimus and axitinib were the most commonly used treatments after second targeted therapy with a TKI and an mTOR inhibitor, respectively. The use of pazopanib as first targeted therapy, and of axitinib and sorafenib as second targeted therapies, increased over time. Efficacy, treatment guidelines and a different MOA were the main reasons for choosing second targeted therapies after failure of a first TKI. These results document patterns of care during a period of rapid and ongoing therapeutic advancement in aRCC. Optimal sequencing of targeted therapies in aRCC warrants further studies. 
